Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

335

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
B-Cell Chronic Lymphocytic Leukemia
Interventions
BIOLOGICAL

FluCAM [Fludara + Campath]

"Phase A: Escalating Doses of alemtuzumab (Campath) Alone~Day 1: alemtuzumab 3 mg intravenously (IV) over 2 hours.~Day 2: alemtuzumab 10 mg IV over 2 hours if 3 mg was tolerated, else repeat 3 mg daily until tolerated.~Day 3: alemtuzumab 30 mg IV over 2 hours if 10 mg was tolerated, else repeat 10 mg daily until tolerated.~Participants were allowed 3-14 days to escalate to 30 mg. Once 30 mg was tolerated, the participant had to begin Phase B within 7 days.~Phase B: FluCAM~Cycle 1: Days 1,2,3 fludarabine phosphate administered at 30 mg/m\^2 over 30 minutes IV, followed within 1 hour by alemtuzumab 30 mg IV over 2 hours. A similar schedule is set for Cycles 2 through 6; duration of alemtuzumab infusions vary from 2-6 hours. Each 28-day period is 1 cycle. Fludarabine phosphate dosage is based on participants' body surface area at the beginning of each cycle. FluCAM administered up to a maximum of 6 cycles, based upon participants' response to therapy and toxicity."

BIOLOGICAL

fludarabine phosphate

Fludarabine phosphate (Fludara) is administered at a dose of 25 mg/m\^2 IV over 15 to 30 minutes daily for 5 consecutive days (days 1 through 5) every 28 days (per package instructions). Each 28-day period is 1 cycle. The dose of fludarabine phosphate will be based on the participant's body surface area as calculated at the beginning of each cycle. Participants treated with fludarabine phosphate up to a maximum of 6 cycles, based upon their response to therapy and toxicity.

Trial Locations (48)

1090

Universitat Wien AKH, Innere Medizin I, Vienna

1431

"Multiprofile Hospital for Active Treatment Alexandrovska", Sofia

1756

National Center for Heamtology and Transfusiology, Sofia

4000

UMHAT St. Georgi, Hematology Clinic, Plovdiv

5800

University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski, Pleven

8036

Medizinische Universitatsklinik Graz, Graz

9010

Multiprofile Hospital for Active Treatment, St. Marina, Varna

10000

Clinical Hospital Merkur, Zagreb

University Hospital Dubrava, Zagreb

11527

"Laikon General Hospital, University of Athens", Goudi

12203

Charite-Universitatsmedizin Berlin Campus Benjamin-Franklin, Berlin

13353

Charite Universitatsklinikum der Humboldt-Universitat zu Berlin, Berlin

20132

Unita Operativa di Medicina Generale Reumatologia e Oncoematologia, Milan

29000

Khmelnitskiy Regional Hospital, Hematology Department, Khmelnitskiy

33916

Florida Cancer Specialists, Fort Myers

49102

City Clinical Hospital #4, Regional Hematology Center, Dnipro

50924

Klinikum der Universitat zu Koln, Klinik 1 fur Innere Medizin, Cologne

51000

Clinical Hospital Center Rijeka, Department of Haematology, Rijeka

59037

CHRU - Hopital Claude Huriez, Lille

61070

Kharkov Regional Clinical Oncology Center, Department of Hematology, Kharkiv

70376

Robert-Bosch Krankenhaus GmbH, Stuttgart

79044

Cherkasskly Oncology Dispensary, Cherkasy

Lviv National Medical University named Danilo Galytcky, Lviv

83045

Donetsk State Medical University, Donetsk

88100

"U.O. Oncologia Medica Azienda Ospedaliera Pugliese-Ciaccio", Cantanzaro

105229

"GU Main Military Clinical Hospital named after acad. N.N.Burdenko of MO of Russia, Haematology Centre 3", Moscow

197089

"GOUVPO Saint-Petersburg State Medical University named after acad I.P.Pavlov of Roszdrav, Bone Marrow Transplantology Clinic", Saint Petersburg

197110

"Saint-Petersburg GUZ City Hospital #31 3, Dynamo Prospect", Saint Petersburg

620102

"State Healthcare Department Sverdlovsk Regional Clinical Hospital #1,", Yekaterinburg

R3E 0V9

Cancer Care Manitoba, Winnipeg

H2L 4M1

Hopital Notre-Dame du CHUM, Montreal

00161

"Istituto di Ematologia Dipartmento di Biotechnologie Celluari ed Ematologia, Universita di Roma La Sapienza", Rome

40-027

Klinika Hematologii i Transplantacji Szpiku, Katowice

93-513

Klinika Hematologii AM, Lodz

71-252

Klinika Hematologii Pomorskiej Akademii Medycznej w Szczecinie, Szczecin

02-097

Katedra i Klinika Hamatologii, Onkologii I Chorob Wewnetrznych AM, Warsaw

50-367

Klinika Hematologii, Nowotworow Krwii 1 Transplantacji Szpiku, Wroclaw

1649-035

Hospital de Santa Maria Servico de Hematologia Clinica/Hospital de dia de Hematologia, Lisbon

3504-509

Hospital de Sao Teotonio, Servico de Hematologia/Hosptial de Dia Oncologico, Viseu

022328

Institutol Clinic Fundeni, Clinica Heamtologie, Bucharest

221 85

University Hospital, Dept. of Hematology, Lund

701 85

Orebro University Hospital, Dep. of Medicine, Örebro

Universitetssjukhuset, Örebro

851 86

Medicin kliniken/Hematologsektionen, Sundsvall

751 85

Akademiska sjukhuset, Uppsala

03022

Institute of Oncology AMS of Ukraine, Kiev

04112

Institute of Hematology and Transfusiology AMS of Ukraine, City Clinical Hospital #9, Kiev

03115

Scientific Centre for Radiation Medicine AMS of Ukraine, Dept of Hematology and Transplantology, Kyiv

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT00086580 - Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients | Biotech Hunter | Biotech Hunter